News Stories

CHICAGO — In this video, James A. Underberg, MD, discusses recommendations from the National Lipid Association for patient-centric management of cholesterol abnormalities, and how they connect with the results of the IMPROVE-IT trial presented at the American Heart Association Scientific Sessions.

Adding ezetimibe to statin therapy further lowered cholesterol levels and resulted in fewer cardiovascular events in patients following heart attack
 

More than a decade ago, researchers from Brigham and Women’s Hospital (BWH) demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events.

On Sunday, Nov. 16, at the American Heart Association (AHA) Scientific Sessions, W. Virgil Brown, MD—Editor-in-Chief of the Journal of Clinical Lipidology and Founding President of the National Lipid Association (NLA)—facilitated and participated in a debate about cholesterol targets. The session (which also featured commentary from Dr. Jennifer Robinson of Iowa City) provided an opportunity to engage in thoughtful dialogue with global cardiovascular thought leaders about cholesterol targets.